Kala
Arlington, United States · Biotechnology · 9 employees
Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors,
Funding history
- Venture - Series Unknown — $2.3M — Feb 2026
- Venture - Series Unknown — $10.7M — Dec 2024
- Venture - Series Unknown — $12.5M — Jun 2024
- Post-IPO Equity — $31.0M — Nov 2022
Recent signals
- Feb 13, 2026: Raised $2.3M in Venture - Series Unknown
- Sep 02, 2025: KALA BIO Appoints Todd Bazemore as President and Chief Executive Officer
- Dec 31, 2024: Raised $10.7M in Venture - Series Unknown
- Dec 30, 2024: KALA BIO Announces $10,750,000 Private Placement
- Jun 28, 2024: Raised $12.5M in Venture - Series Unknown
- Jun 27, 2024: KALA BIO Announces $12,500,000 Private Placement with SR One and ADAR1 Capital Management
- Nov 28, 2022: Raised $31.0M in Post-IPO Equity
See plans & pricing → Track Kala’s funding, hiring, and signals — with verified contacts — on Fundz.